Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Seres Therapeutics (Nasdaq: MCRB) announced that its management will participate in the H.C.
Rhea-AI Summary
Seres Therapeutics (Nasdaq: MCRB) announced that its management will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY. The company will present a corporate overview at 2:00 p.m. ET on September 15, 2026, with a live webcast and replay available via the Events and Presentations section of its website.
Positive
- None.
Negative
- None.
News Market Reaction – MCRB
In the Sep 1 session, MCRB gained 5.50%, reflecting a notable positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 05 | Q2 earnings report | Positive | -4.7% | Net income and Nestlé milestone gain contrasted with ongoing operating and financing risks. |
| Jul 08 | SER-155 clinical data | Positive | -12.3% | Clinical response and remission data were followed by a negative 24-hour reaction. |
| Jun 25 | SER-155 webcast notice | Neutral | +0.5% | The company scheduled a webcast to discuss investigator-sponsored trial results. |
| Jun 05 | Balance sheet transactions | Positive | -3.2% | Nestlé payment and lease restructuring extended the projected operating cash runway. |
| May 12 | Investor conference notice | Neutral | +1.5% | Management announced a company overview presentation at an H.C. Wainwright conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
MCRB's two recent positive clinical or financial announcements were followed by negative reactions, while conference and webcast notices had positive reactions.
Key Terms
live biotherapeutics technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 28th Annual Global Investment Conference taking place in New York, NY and will present a company overview at 2 p.m. ET on September 15, 2026.
A live webcast of the presentation will be accessible here and will be available for replay on the “Events and Presentations” section of Seres’ website following the event.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products, designed to address unmet needs in oncology that can lead to interruption to patients' cancer care and/or mortality, and to treat inflammatory and immune diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal (GI) tract. The Company previously led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, an investigational cultivated multi-strain biotherapeutic, which has received Breakthrough Therapy and Fast Track designations, is being advanced for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant, and is Phase 2 ready, pending receipt of funding. SER-155 is also being developed to address immune checkpoint inhibitor-related enterocolitis (irEC) to provide an immunosuppressive-free alternative and enable patients to continue their ICI cancer therapy. Having recently reported promising results from an investigator sponsored trial, Seres is evaluating the design of a Phase 2 study in irEC. The Company is advancing IND-enabling studies for SER-603, which is in development for inflammatory bowel disease. Mechanistically, Seres' biotherapeutics target the mucosal epithelial barrier-immune interface and are optimized to modulate host function to increase mucosal epithelium integrity, induce immune homeostasis, and prevent the colonization and overgrowth of harmful bacteria in the GI tract. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
